SEC Comment Letter 0000000000-24-004609 to Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc.
Date: April 25, 2024 · CIK: 0001636282 · Accession: 0000000000-24-004609
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278810
Letter
United States securities and exchange commission logo April 25, 2024 Heidy King-Jones Chief Legal Officer Spyre Therapeutics, Inc. 221 Crescent Street Building 23, Suite 105 Waltham, MA 02453 Re:Spyre Therapeutics, Inc. Registration Statement on Form S-1 Filed April 19, 2024 File No. 333-278810 Dear Heidy King-Jones: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Branden Berns
Show Raw Text
United States securities and exchange commission logo
April 25, 2024
Heidy King-Jones
Chief Legal Officer
Spyre Therapeutics, Inc.
221 Crescent Street
Building 23, Suite 105
Waltham, MA 02453
Re:Spyre Therapeutics, Inc.
Registration Statement on Form S-1
Filed April 19, 2024
File No. 333-278810
Dear Heidy King-Jones:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Branden Berns